Method and apparatus for forming porous metal implants

Information

  • Patent Grant
  • 7635447
  • Patent Number
    7,635,447
  • Date Filed
    Friday, February 17, 2006
    18 years ago
  • Date Issued
    Tuesday, December 22, 2009
    15 years ago
Abstract
A method for providing a porous metal implant. A mixture of a biocompatible metal, a spacing agent, and a binder is provided. The mixture is formed into a shaped the spacing agent is removed to form a plurality of pores in the implant. A shaped porous metal implant is also provided.
Description
CROSS-RELATED APPLICATIONS

The present application is related to U.S. patent application Ser. No. 11/357,868 entitled “Method and Apparatus for Use of Porous Implants”, the disclosure of which is incorporated by reference. “Method and Apparatus for Use of Porous Implants” is filed concurrently herewith and is commonly assigned to Biomet Manufacturing Corp. of Warsaw, Ind.


FIELD

The present teachings relate to porous metal implants and methods of manufacture.


BACKGROUND

Porous metal implants are used to promote ingrowth of surrounding bony tissue and soft tissues into the implant. When the porosity, integrity and continuity of the metals are sufficient, porous implants serve as a scaffold for tissue ingrowth to provide the desired load-bearing strength to the implant site.


The porous implants can be formed by removing pieces from a metal substrate, such as by etching a solid piece of metal. The implants can also be formed by using small metal particles such as powders. Where metal powders are used, multi-step heat and pressure application steps can compromise the desired integrity and load-bearing strength of the implant due to shifts in the structure during initial molding and when transferring the implant between the various furnaces, pressure chambers, machining apparatus, etc. Furthermore, temperatures and pressures must accommodate the removal of foaming agents or spacing agents without further compromising the implant. These multiple considerations in forming the implant limit the formation of complex shapes from the starting materials because switching between the various pressing, heating, shaping, and other processing steps can cause the implant to become misshapen. In other systems using metal powders, a binding or interface layer must be used in order to attach the porous structure to a substrate. Many of these methods use different metals to form the substrate and the porous layer, leading to corrosion and a reduction in the life span of the implant.


It may be desirable to provide a porous metal implant which has one or more of these properties: a desirable porosity, is shaped and processed easily, readily forms three-dimensional complex shapes, maintains its intended shape throughout the various processing steps, promotes soft and hard tissue ingrowth, and is suitable for load-bearing applications.


SUMMARY

The present teachings provide methods for preparing a porous metal implant comprising: preparing a mixture of a biocompatible metal powder; a spacing agent; and a non-polar liquid binder, where the spacing agent is substantially insoluble in the non-polar liquid binder. The mixture is formed into a shape and the non-polar liquid binder and the spacing agent are removed from the mixture to form a plurality of pores within the metal implant.


The biocompatible metal powder can be selected from titanium, titanium alloys, cobalt, cobalt alloys, chromium, chromium alloys, tantalum, tantalum alloys, and stainless steel. The biocompatible metal powder can have a particle size of from about 5 micrometers to about 1500 micrometers. The spacing agent can be selected from hydrogen peroxide, urea, ammonium bicarbonate, ammonium carbonate, ammonium carbamate, calcium hydrogen phosphate, naphthalene, and mixtures thereof. The spacing agent can have a particle size of from about 1 micrometer to about 1500 micrometers. The non-polar liquid binder and the spacing agent can form a suspension. The non-polar liquid binder can comprise d-limonene (commercially available from Florida Chemical Company, Inc., Winter Haven, Fla., U.S.). The binder and the spacing agent can be cohesive during formation of the mixture and removal of the spacing agent. The mixture can be homogenous. The mixture can be formed into a shape suitable for application to an augment site.


Forming the mixture into a shape can be achieved with pressing techniques such as uniaxial pressing, isostatic pressing, and split die techniques and can be conducted at or below about room temperature. The pressing technique can be conducted at a pressure of from about 100 megapascals to about 500 megapascals. Generally, a suitable pressure is at about or above 150 megapascals or above 170 megapascals. Removing the spacing agent can include subliming the mixture at a temperature at which the metal does not react with the spacing agent. The mixture can be sintered under vacuum pressure after removing the spacing agent. The formed shape can be further shaped, machined, attached to a substrate, or welded to a substrate.


The porosity of the implant can be varied by using metal powder(s) or spacing agent(s) of at least two different sizes. The porosity can be continuous or it can be a gradient. The gradient can include porosity changes of from about 1% to about 80%. The implant can also be coated with agents such as resorbable ceramics, resorbable polymers, antibiotics, demineralized bone matrix, blood products, platelet concentrate, allograft, xenograft, autologous, and allogeneic differentiated or stem cells, peptides, nutrients, vitamins, growth factors, and combinations thereof.


The present teachings also provide moldable compositions for providing a porous metal implant. The compositions include a biocompatible metal powder; a spacing agent; and a non-polar liquid binder, where the spacing agent is substantially insoluble in the non-polar liquid binder. The biocompatible metal powder can independently comprise Ti-6Al-4V, the spacing agent can comprise ammonium bicarbonate, and the non-polar liquid binder can comprise d-limonene. The materials can be selected such that the sublimination temperature of the spacing agent and the sublimination temperature of the non-polar liquid binder differ by less than about 200° C. The moldable composition can include a securing element.


The present teachings also provide methods of securing a moldable composition, comprising: placing a securing element about at least a portion of the mixture; molding the mixture into a formed shape while the mixture is in the securing element; subliming the spacing agent and non-polar liquid binder from the formed shape; removing the securing element; and sintering the formed shape. The securing element can be a flexible material and can be secured about at least a portion of the mixture using a vacuum seal. The foil can have a thickness of about 1 millimeter. The securing element can enhance the cohesiveness of the formed shape for at least three days.


The present teachings also provide methods for preparing a porous metal implant comprising: preparing a mixture comprising a biocompatible metal powder, a spacing agent, and a non-polar liquid binder, where the spacing agent is substantially insoluble in the non-polar liquid binder; forming the mixture into a shape; and thermal cycling the mixture within a single heating unit to remove the spacing agent and the non-polar liquid binder and sinter the metal powder to form a plurality of pores within the metal implant. The mixture can be continuously maintained in the heating unit until the metal powder combines to form the metal implant. The thermal cycling can include at least one sintering and at least one quenching.


Further areas of applicability of the present teachings will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts a mixture used to prepare a porous metal implant according to various embodiments;



FIG. 2 depicts a porous metal implant according to various embodiments;



FIG. 3A through 3H depict various shaped porous metal implants according to various embodiments;



FIG. 4A depicts a secured preparation to form a porous metal implant according to various embodiments; and



FIG. 4B depicts an interior view of the secured preparation depicted in FIG. 4A.



FIG. 5A through 5C depict porous metal implants used in conjunction with an acetabular cup prosthesis according to various embodiments;



FIG. 6 is a diagram of a method of forming a porous metal implant; and



FIG. 7 depicts a porous metal implant attached to a solid core according to various embodiments.





DETAILED DESCRIPTION

The following description is merely exemplary in nature and is in no way intended to limit the teachings, their application, or uses. Although various embodiments may be described in conjunction with a porous metal implant for use with a knee or hip prosthetic device, it is understood that the implants and methods of the teachings can be of any appropriate substrate or shape and can be used with any appropriate procedure and not solely those illustrated.


Referring to FIGS. 1 and 2, a porous metal implant 10 can be formed from a mixture of a metal powder 12, a spacing agent 14, and a non-polar liquid binder 16. The porous metal implant 10 is formed by heating the mixture to a temperature sufficient to remove the spacing agent 14 and non-polar liquid binder 16 thereby leaving a plurality of pores 18 between the interconnected metal powder 12 particles.


The metal powder 12 can be any metal or alloy that is suitable for use as an implant and provides the desired strength, load bearing capabilities, and ability to become porous. Suitable exemplary metals include titanium, cobalt, chromium, or tantalum, alloys thereof, stainless steel, and combinations thereof. The metal powder 12 particles can have a diameter of from about 5 micrometers to about 1500 micrometers. In various embodiments, the metal powder 12 can be of at least two different particle sizes.


The spacing agent 14 provides the pores 18 of the porous metal implant 10. The spacing agent 14 can be removable from the mixture and it may be desirable if the spacing agent 14 does not leave residue in the porous metal implant 10. It may be further desirable that the spacing agent 14 expands or contracts to supplement the formation of pores 18 of a desired size within the porous metal implant 10. The spacing agent 14 can be selected from the group consisting of hydrogen peroxide, urea, ammonium bicarbonate, ammonium carbonate, ammonium carbamate, calcium hydrogen phosphate, naphthalene, and mixtures thereof, or can be any other suitable subliming and space forming material. Generally, the spacing agent 14 has a melting point, boiling point, sublimation temperature, etc. of about less than 250° C. The spacing agent 14 provides the macroporosity and microporosity of the biocompatible metal powder 12 before and during the thermal cycling processes, described later herein, because after the spacing agent 14 decomposes and metallurgical bonds form between the metal powder 12 particles, pores 18 or gaps remain where the spacing agent 14 was located.


The non-polar liquid binder 16 is used to improve the cohesiveness of the mixture because the non-polar liquid binder 16 keeps all mixture components in close proximity and does not dissolve the spacing agent 14. The non-polar liquid binder 16 can be a volatile compound with a boiling point sufficiently close to the sublimation or decomposition point of the spacing agent 14. In various embodiments, that temperature difference is less than about 200° C. In still other embodiments, that difference is less than about 100° C. The close range of the sublimation temperature of the spacing agent 14 and the boiling point of the non-polar liquid binder 16, allows for a single step removal of the spacing agent 14 and the non-polar liquid binder 16.


The non-polar liquid binder 16 can be a botanical organic compound. An example of such a binder is limonene (4-isopropenyl-1-ethylcyclohexene), including any stereoisomers thereof, such as d-limonene, l-limonene, and mixtures thereof. In various embodiments, d-limonene can be used. The d-limonene can be derived from citrus fruits (orange, lemon, lime, tangerine, etc.), from other plant materials such as those in the GENUS Pinus (from pine tree needles and branches), Peucedanum (from dill plants), and other plants. In embodiments where the non-polar binder 16 is derived from a citrus fruit, it is preferred that the major component is d-limonene and the balance consists of other terpene hydrocarbons and oxygenated compounds such as octanal, myrcene, alpha-pinene, and linalool. The d-limonene can be synthesized in a laboratory (non-fruit derived) or processed from the plant to be of food or technical grades. Other suitable non-polar liquid binders 16 can include high concentrations of terpenes, relative to other components in the material, such as those derived from cedar wood, Copaiba Balsam, ginger, hemp, hops, bergamot, dog fennel, turpentine, pinene, and sylvestrene, for example. In various embodiments, a mixed terpene solution can be used, the mixture consisting of various concentrations of terpenes, sesquiterpenes, and polyterpenes. It is understood that the non-polar liquid binder 16 is not limited to botanicals, but also includes any non-polar liquid having the desired volatility and/or compatibility with the metal powder 12 and the spacing agent 14, etc., for example mineral oil.


The mixture of non-polar liquid binder 16, spacing agent 14, and metal powder 12 can be made homogenous by mixing. In various embodiments, the ratio of metal powder 12 to spacing agent 14 can be about 1:1 up to about 10:1. The non-polar liquid binder 16 can be in a ratio of from about 1 part binder (in milliliters) to about 10 parts of solid (spacing agent 14 and biocompatible metal powder 12, in grams) up to about 1 part binder 16 to about 30 parts of solid.


Altering the ratios of the mixture components and/or the sizes of the components can provide an implant having a higher or lower porosity, enhanced load-bearing abilities, and can help to tailor the porous metal implant 10 for a particular region of the body. Utilizing a ratio of metal powder 12 to spacing agent 14 of 8:1 will provide an dense implant 10 having very fine pores. In another example, in a mixture having a 3:1 metal powder 12 to spacing agent 14 ratio, if the spacing agent 14 has a diameter of at least about 25 micrometers and the metal powder 12 has a diameter of about 10 micrometers, large pores result. If the metal powder 12 and spacing agent 14 diameter sizes were reversed, smaller pores would result.


The mixture can also include metal powders 12 of different particulate sizes. By including metal powder 12 particulates of at least two different sizes, a porosity gradient can be achieved. The porosity gradient can be such that the porosity of the implant 10 increases or decreases by up to about 80% across the body of the implant 10. The porosity gradient can be continuous and scale up (or down) to a desired amount, or the porosity gradient can include differing porosity regions (e.g., 80% porosity region transitions to a 40% porosity region which transitions to a 75% porosity region). The transitions between the regions can be continuous in the porous metal implant 10. To provide the different porosities, a mixture corresponding to a particular porosity is stacked on top of or adjacent to a mixture having a different porosity.


The mixture can be formed into a regular or geometric shape. As depicted in FIGS. 3A-3F, the shaped mixture can be used to form implants that include solid body cylinders, blocks, discs, cones and also include hollow or recessed regions as depicted in FIGS. 3B and 3C. The mixture can also be a free form shape such as a shape corresponding to an augment site in a recipient to provide a prosthetic specifically tailored to a recipient. The combination of the metal powder 12, spacing agent 14, and non-polar liquid binder 16 allows for shaping the mixture prior to any heat treatments described later herein. Shaping the mixture prior to sintering simplifies the process of forming the porous metal implant 10 by eliminating the need to transfer the mixture from between a heat source for subliming the spacing agent 14, a different heat source to remove the non-polar liquid binder 16, and any machines.


Referring to FIGS. 4A and 4B, to facilitate forming the porous metal implant 10 into a shape, the mixture can be fixed into place with a securing element 20. The securing element 20 can contact at least a region of the mixture for the porous metal implant 10. The securing element 20 can be made of a flexible material that is substantially non-reactive with the metal powder 12, the spacing agent 14, and/or the non-polar liquid binder 16. The securing element 20 can be a metal foil, such as aluminum foil for example. The securing element 20 can also be a rubber material or a silicone polymer. The thickness of the securing element 20 can be greater than about 1 millimeter, but it can be scaled up or down depending on the size of the porous metal implant 10 and the ratio of the non-polar liquid binder 16 to the metal powder 12 and the spacing agent 14. For example, if the mixture had a critical volume of the non-polar liquid binder 16, it may be desirable to employ a thicker foil securing element 20 to prevent any unintentional release of the non-polar binder 16 from the wrapped package. The securing element 20 can be a band or piece of foil that can be attached to a portion of the mixture, folded upon itself, or form a pouch to envelop the mixture. The packet of the mixture wrapped in the securing element 20 can be formed into a shape, such as those in FIGS. 3A-3H without damaging the mixture or disrupting a porosity gradient, if any, in the material.


The securing element 20 increases the time the mixture can be stored prior to thermal cycling. The securing element 20 increases the cohesiveness of the mixture of the metal powder 12, the spacing agent 14, and the binder 16 to reduce unintentional separation of disruption of the material, even, for example, when the mixture is arranged to provide a porosity gradient. The cohesiveness refers to the ability of the metal powder 12, the spacing agent 14, and the binder 16 to be held together as a solid mass of the respective discrete materials. For example, the mixture can be held for several hours, from 1 to 7 days, from about 3 to about 12 weeks, for a period of several years, or longer. In embodiments where the non-polar liquid binder 16 is d-limonene, the mixture is particularly shelf-stable. Shelf-stability is particularly advantageous when preparation of the mixture needs to be completed at an earlier time than the sintering of the mixture or when resources are limited as to the amount of heating units, such as ovens, furnaces, etc. available and the number/variety of porous metal implants 10 that need to be created.



FIG. 6 generally details the methods of forming the porous metal implant 10. Forming the porous metal implant 10 generally includes preparing the mixture 100, shaping the mixture 102, and thermal cycling the mixture to form the porous body 104. Preparing the mixture 100 is detailed above herein. Shaping the mixture can include pressing the mixture in a suitable device including an isostatic press, uniaxial press, or a split die to form a compact. The mixture can be placed in a rubber mold or any other suitable mold to maintain the shape during the press. In various embodiments, the press is conducted at or below about 200° C. or at or below about room temperature. For example, a cold isostatic press can be used where the temperature is less than about 200° C. The metal-binder-spacing agent mixture is placed in a cold isostatic press bag and pressure is applied. An alternate forming includes shaping the blocks formed from the cold isostatic or other pressing into specific shapes. The pressure used in from about 345 megapascals to about 420 megapascals. The formed shapes or blocks can be machined into particular shapes (e.g., acetabular cup). The pressed compacts can also be stored in airtight sealed containers or foil bags.


The thermal cycling 104 includes removing the spacing agent 14 and the non-polar liquid binder 16 and sintering the mixture to create metallic interparticle bonds and provide the physical and mechanical properties of the porous metal implant 10. The thermal cycling 104 can include at least one sintering 106 and at least one quenching 108. Sintering conditions (temperature, time, and atmosphere) must be such that the metallic interparticle bonds are created while extensive densification is avoided. The sintering can be performed in a controlled atmosphere, such as a vacuum for example, to prevent formation of oxides on the metal surface. Thermal cycling can be a single-oven or furnace process and require no manipulation of the mixture between the stages of forming the mixture and removing formed porous metal implant 10. It is also understood that the thermal cycling of the materials described herein can be performed in multiple ovens.


In an exemplary cycling, the compact can be initially heated at from about 50° C. to about 250° C. to remove the non-polar liquid binder 16 and the spacing agent 14. The exact temperature can be selected depending on the combination of the non-polar liquid binder 16 and the spacing agent 14, vacuum conditions, etc. It is desirable to remove the spacing agent 14 at a temperature at which the metal 12 does not react with the spacing agent 14. In various embodiments, that temperature can be at from about 25° C. to about 500° C. In various other embodiments, that temperature can be a temperature less than the melting point of the metal powder 12. For example, in an embodiment where the non-polar liquid binder 16 comprises d-limonene having a boiling point of 175° C. and an ammonium bicarbonate spacing agent having a boiling temperature of 108° C. and begins to decompose carbon dioxide. A suitable initial cycling temperature can be at about at least 60° C. or higher, but preferably under the sintering temperature of the selected metal powder 12. It may be desirable for the initial cycle temperature to be at about or above the boiling point or the sublimation point or decomposition of the component having the highest temperature value. In the above example, it may be desirable to use an initial cycling temperature of about 175° C.


A first sintering of the compact is conducted to transform the compact (substantially free from metallurgical bonds between the metal powder 12 particles) to the implant 10 having the metallurgical bonds. The temperature can be increased in the chamber (2° C., 5° C., 10° C., 20° C., 50° C., for example) at time intervals (5 seconds up to 15 minutes). Once the desired temperature or “hold temperature” is reached, the mixture is maintained at the hold temperature from about 1 hour to about 10 hours or from about 2 hours to about 6 hours to create the metallurgical bonds between the metal powder 12 particles. The use of temperature intervals allows for elimination of separate steps or separate ovens used to remove the spacing agent 14 and the non-polar liquid binder 16.


The porous metal implant 10 is quenched or rapidly cooled to generate a phase of hardened metal known as the martensite phase. Quenching can be achieved by direct quenching, fog quenching, hot quenching, interrupted quenching, selective quenching, slack quenching, spray quenching, and/or time quenching. Quenching can be performed in the sintering oven without moving the implant. For example, with fog quenching, a fog could be distributed through the sintering oven to quench the metal and the fog could be subsequently vacuumed out. Once the sintering oven was completely purged of the fog, an inert gas could be reintroduced into the oven and the thermal cycling would continue. The porous metal implant 10 can be quenched at or below room temperature or the porous metal implant 10 can be quenched to a warmer temperature (over about 40° C. For example, the porous metal implant 10 can be quenched to a temperature closer to the starting temperature of the subsequent sintering or heating. In such embodiments, if the first sintering hold temperature was over 1000° C., the quenching can reduce the temperature of the porous metal implant 10 to about 400° C.


A second sintering can also be employed. The second sintering can be conducted under similar conditions to the first sintering or the hold temperature can be reduced as compared with the first sintering. For example, where the first hold temperature was over 1000° C., the second hold temperature can be from about 500° C. to about 900° C. The second hold time can be of the same duration or a different duration than the first hold time. In various embodiments, the hold time can be from about 1 hour to about 10 hours or from about 2 hours to about 6 hours. Quenching as detailed above can also be repeated. Furthermore, additional sintering can be performed.


After completion of sintering, a final thermal treatment can include heating the porous implant 10 at a temperature below the sintering temperature of the metal powder 12 or at a temperature that is a fraction of the first sintering temperature. In various embodiments, it may be desirable to employ a fraction gradient temperature reduction. For example, a first sintering can be up to a temperature of about 1200° C., a second sintering can be up to about 800° C., and the final thermal treatment can be up to about 400° C. Each successive heating can be reduced by a predetermined number of degrees, for example about 300° C. to about 400° C. Between each heating, quenching can be employed to increase the hardness and longevity of the porous metal implant 10, while preventing the crumbling and misshapen attributes caused by moving the materials between the various ovens or machines, for example. In various embodiments, it may be desirable to quench the porous implant to about room temperature during the final thermal cycling.


The thermal cycling can be conducted in a vacuum or under reduced pressure of inert gas. It may be desirable to conduct the sintering in an inert atmosphere (in argon gas, for example). The vacuum and/or the inert atmosphere will prevent solid solution hardening of the surface of the porous implant 10 as a result of inward diffusion of oxygen and/or nitrogen into the metal.


The porous implant 10 can be further shaped and machined to adjust the tolerances of the material and can be used to add features such as grooves, indentations, ridges, channels, etc. The machining can also be used to form complex shapes such as those depicted in FIGS. 3G and 3H.


The porous metal implant 10 can be attached to a metal substrate 22 by any suitable means, such as welding, sintering, using a laser, etc. In various embodiments, the metal substrate is the same metal as the metal powder 12. The metal substrate can be a prosthetic device, such as an acetabular cup, depicted in FIG. 3G, or to the condoyle surfaces, depicted in FIG. 3H. The temperature and pressure conditions used to attach the metal substrate to the porous body can be such that diffusion and metallurgical bonding between the substrate surface areas and the adjacent porous metal surfaces will be achieved. For example, in an embodiment where the porous metal segment and metal substrate are heated to 1000° C., the pressure applied must be such that the resultant implant 10 has structural integrity for implanting into a recipient without significant defects.


The metal substrate 22 can be prepared prior to attaching the porous body. The metal substrate 22 can be acid etched, subjected to an acid bath, grit blasted, or ultrasonically cleaned for example. Other preparations include adding channels, pits, grooves, indentations, bridges, or holes to the metal substrate 22. These additional features may increase the attachment of the porous metal body to the underlying metal substrate. As depicted in FIGS. 5B and 5C, the porous metal implant 10 body can be only partially attached to the metal substrate 22 at specific structural points. Depicted as an acetabular cup 24, the cup 24 includes a ring 26 and the porous implant 10 body attaches to the ring 26 using mechanical interface 28 and metallurgical bonds. FIG. 5B depicts a C-shaped mechanical interface and FIG. 5C depicts a I-beam type mechanical interface. The percentage of the porous metal implant 10 attached using metallurgical bonds is less than about 40%. The porous metal implant 10 can also be attached to a solid core or solid body 30 as shown in FIG. 7.


The porous metal implant 10 can also be attached as part of an orthopaedic insert, such as those disclosed in U.S. patent application Ser. No. 11/111,123 filed Apr. 21, 2005, incorporated by reference. The porous metal implant 10 can also be used to form a geostructure, which is a three-dimensional geometric porous engineered structure that is self supporting and is constructed of rigid filaments joined together to form regular or irregular geometric shapes. The structure is described in more detail in U.S. Pat. No. 6,206,924, which is incorporated by reference.


Additional agents can be coated onto or in at least a surface of the porous metal implant 10. Agents include resorbable ceramics, resorbable polymers, antibiotics, demineralized bone matrix, blood products, platelet concentrate, allograft, xenograft, autologous and allogeneic differentiated cells or stem cells, nutrients, peptides and/or proteins, vitamins, growth factors, and mixtures thereof, which would facilitate ingrowth of new tissue into the porous metal implant 10. For example, if the additional agent is a peptide, an RGB peptide can be advantageously incorporated into the implant.


The description of the teachings is merely exemplary in nature and, thus, variations that do not depart from the gist of the teachings are intended to be within the scope of the teachings. Such variations are not to be regarded as a departure from the spirit and scope of the teachings.

Claims
  • 1. A method for preparing a porous metal implant comprising: a. preparing a mixture comprising: i. a biocompatible metal powder;ii. a spacing agent selected from the group consisting of hydrogen peroxide, urea, ammonium carbonate, ammonium bicarbonate, ammonium carbamate, calcium hydrogen phosphate, naphthalene, and mixtures thereof; andiii. a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder;b. forming the mixture into a shape; andc. removing the spacing agent by melting or sublimation thereof to form a plurality of pores within the metal implant.
  • 2. The method of claim 1, wherein the biocompatible metal powder is selected from the group consisting of titanium, titanium alloys, cobalt, cobalt alloys, chromium, chromium alloys, tantalum, tantalum alloys, and stainless steel.
  • 3. The method of claim 1, wherein the metal powder has a particle size of from about 5 micrometers to about 1500 micrometers.
  • 4. The method of claim 1, wherein the spacing agent has a particle size of from about 1 micrometer to about 1500 micrometers.
  • 5. The method of claim 1, wherein the non-polar liquid binder and the spacing agent form a suspension.
  • 6. A method for preparing a porous metal implant comprising: a. preparing a mixture comprising: i. a biocompatible metal powder;ii. a spacing agent; andiii. a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder;b. forming the mixture into a shape; andc. removing the spacing agent to form a plurality of pores within the metal implant, wherein the non-polar liquid binder comprises d-limonene.
  • 7. The method of claim 1, wherein the binder and the spacing agent are cohesive during formation of the mixture and removal of the spacing agent.
  • 8. The method of claim 1, wherein the mixture is a homogenous mixture.
  • 9. The method of claim 1, wherein forming the mixture into a shape comprises molding the mixture into a shape suitable for application to an augment site.
  • 10. The method of claim 1, wherein forming the mixture into a shape is selected from pressing techniques selected from the group consisting of uniaxial pressing, isostatic pressing, and split die techniques.
  • 11. The method of claim 10, wherein said forming is conducted at a temperature at or below about room temperature.
  • 12. The method of claim 10, wherein the pressing technique is conducted at about above 150 megapascals.
  • 13. The method of claim 12, wherein the pressing technique is conducted at above about 170 megapascals.
  • 14. The method of claim 1, wherein removing the spacing agent comprises subliming the mixture at which the metal does not react with the spacing agent.
  • 15. The method of claim 1, further comprising sintering the metal under vacuum pressure after removing the spacing agent.
  • 16. The method of claim 15, further comprising at least one of shaping the implant, machining the implant, attaching the implant to a substrate, or welding the porous implant to a substrate.
  • 17. The method of claim 1, wherein the metal powder includes at least two different sizes.
  • 18. The method of claim 1, further comprising providing a gradient porosity in the metal implant.
  • 19. The method of claim 18, wherein the gradient porosity is from about 1% to about 80%.
  • 20. The method of claim 1, further comprising coating at least a surface of the porous metal implant with an agent selected from the group consisting of resorbable ceramics, resorbable polymers, antibiotics, demineralized bone matrix, blood products, platelet concentrate, allograft, xenograft, autologous and allogeneic differentiated cells or stem cells, peptides, nutrients, vitamins, growth factors, and mixtures thereof.
  • 21. A moldable mixture for providing a porous metal implant comprising: a. a biocompatible metal powder;b. a spacing agent; andc. a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder, wherein the difference in the sublimation temperature of the spacing agent and the sublimation temperature of the non-polar liquid binder is less than about 200° C.
  • 22. The moldable mixture according to claim 21, wherein the biocompatible metal powder comprises Ti-6Al-4V.
  • 23. The moldable mixture according to claim 21, wherein the spacing agent comprises ammonium bicarbonate.
  • 24. A moldable mixture for providing a porous metal implant comprising: a. a biocompatible metal powder;b. a spacing agent; andc. a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder, wherein the non-polar liquid binder is d-limonene.
  • 25. The moldable mixture according to claim 21, further comprising a securing element.
  • 26. A method of securing the moldable mixture of claim 25, comprising: a. placing a securing element about at least a portion of the mixture;b. molding the mixture into a formed shape while the mixture is in the securing element;c. subliming the spacing agent and non-polar liquid binder from the formed shape;d. removing the securing element; ande. sintering the formed shape.
  • 27. The method of claim 26, wherein the securing element is made of a flexible material.
  • 28. The method of claim 27, wherein the flexible material is selected from a metal foil, rubber, or a silicone polymer.
  • 29. A method of securing a moldable mixture for providing a porous metal implant comprising: a. providing a mixture comprising a biocompatible metal powder, a spacing agent, and a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder;b. placing a securing element comprising a metal foil about at least a portion of the mixture;c. molding the mixture into a formed shape while the mixture is in the securing element;d. subliming the spacing agent and non-polar liquid binder from the formed shape;e. removing the securing element; andf. sintering the formed shape.
  • 30. The method of claim 26, wherein the securing element is vacuum sealed about at least a portion of the mixture.
  • 31. A method for preparing a porous metal implant comprising: a. preparing a mixture comprising: i. a biocompatible metal powder;ii. a spacing agent; andiii. a non-polar liquid binder comprising d-limonene, wherein the spacing agent is substantially insoluble in the non-polar liquid binder;b. forming the mixture into a shape; andc. thermal cycling the mixture within a single heating unit to remove the spacing agent and the non-polar liquid binder and sinter the metal powder to form a plurality of pores within the metal implant.
  • 32. The method according to claim 31, further comprising continuously maintaining the mixture in the heating unit until the metal powder combines to form the metal implant.
  • 33. A method for preparing a porous metal implant comprising: a. preparing a mixture comprising: i. a biocompatible metal powder;ii. a spacing agent; andiii. a non-polar liquid binder, wherein the spacing agent is substantially insoluble in the non-polar liquid binder;b. forming the mixture into a shape; andc. thermal cycling the mixture within a single heating unit to remove the spacing agent and the non-polar liquid binder and sinter the metal powder to form a plurality of pores within the metal implant, wherein the thermal cycling includes at least one sintering and at least one quenching.
  • 34. The method according to claim 1, wherein the spacing agent comprises ammonium bicarbonate.
  • 35. The method according to claim 34, wherein the removing of the spacing agent comprises sublimation of the spacing agent.
US Referenced Citations (410)
Number Name Date Kind
3353259 Kirkpatrick Nov 1967 A
3605123 Hahn Sep 1971 A
3677795 Bokros et al. Jul 1972 A
3808606 Tronzo May 1974 A
3840904 Tronzo Oct 1974 A
3855638 Pilliar Dec 1974 A
3896500 Rambert et al. Jul 1975 A
3905777 Lacroix Sep 1975 A
3906550 Rostoker et al. Sep 1975 A
3938499 Bucalo Feb 1976 A
3986212 Sauer Oct 1976 A
4051559 Pifferi Oct 1977 A
4164794 Spector et al. Aug 1979 A
4168326 Broemer et al. Sep 1979 A
4184213 Heimke Jan 1980 A
4187559 Grell et al. Feb 1980 A
4205400 Shen et al. Jun 1980 A
4206271 Norling et al. Jun 1980 A
4217666 Averill Aug 1980 A
4224698 Hopson Sep 1980 A
4234972 Hench et al. Nov 1980 A
4285070 Averill Aug 1981 A
4307472 Morris Dec 1981 A
4309488 Heide et al. Jan 1982 A
4330891 Brånemark et al. May 1982 A
4345339 Müller et al. Aug 1982 A
4351069 Ballintyn et al. Sep 1982 A
4355428 Deloison et al. Oct 1982 A
4362681 Spector et al. Dec 1982 A
4479271 Bolesky et al. Oct 1984 A
4542539 Rowe, Jr. et al. Sep 1985 A
4563778 Roche et al. Jan 1986 A
4566138 Lewis et al. Jan 1986 A
4570271 Sump Feb 1986 A
4612160 Donlevy et al. Sep 1986 A
4636219 Pratt et al. Jan 1987 A
4644942 Sump Feb 1987 A
4659331 Matthews et al. Apr 1987 A
4666450 Kenna May 1987 A
4685923 Mathys Aug 1987 A
4693721 Ducheyne Sep 1987 A
4715859 Schelhas et al. Dec 1987 A
4715860 Amstutz et al. Dec 1987 A
4743256 Brantigan May 1988 A
4743262 Tronzo May 1988 A
4756862 Spector et al. Jul 1988 A
4769041 Morscher Sep 1988 A
4778473 Matthews et al. Oct 1988 A
4778474 Homsy Oct 1988 A
4795469 Oh Jan 1989 A
4801301 Noiles Jan 1989 A
4813959 Cremascoli Mar 1989 A
4840632 Kampner Jun 1989 A
4842606 Kranz et al. Jun 1989 A
4851006 Tuke Jul 1989 A
4854496 Bugle Aug 1989 A
4863474 Brown et al. Sep 1989 A
4863475 Andersen et al. Sep 1989 A
4863538 Deckard Sep 1989 A
4871368 Wagner Oct 1989 A
4883490 Oh Nov 1989 A
4883491 Mallory et al. Nov 1989 A
4892549 Figgie, III et al. Jan 1990 A
4904265 MacCollum et al. Feb 1990 A
4919675 Dietschi et al. Apr 1990 A
4923473 Griss et al. May 1990 A
4936847 Manginelli Jun 1990 A
4936856 Keller Jun 1990 A
4936861 Muller et al. Jun 1990 A
4944759 Mallory et al. Jul 1990 A
4950270 Bowman et al. Aug 1990 A
4950299 Noiles Aug 1990 A
4955919 Pappas et al. Sep 1990 A
4957819 Kawahara et al. Sep 1990 A
4963154 Anapliotis et al. Oct 1990 A
4969907 Koch et al. Nov 1990 A
4969910 Frey et al. Nov 1990 A
4976738 Frey et al. Dec 1990 A
4978355 Frey et al. Dec 1990 A
4978356 Noiles Dec 1990 A
4978358 Bobyn Dec 1990 A
4997445 Hodorek Mar 1991 A
5004476 Cook Apr 1991 A
5009665 Serbousek et al. Apr 1991 A
5013324 Zolman et al. May 1991 A
5018285 Zolman et al. May 1991 A
5019105 Wiley May 1991 A
5021062 Adrey et al. Jun 1991 A
5021063 Täger Jun 1991 A
5024670 Smith et al. Jun 1991 A
5027998 Bugle Jul 1991 A
5030233 Ducheyne Jul 1991 A
5047182 Sundback et al. Sep 1991 A
5080672 Bellis Jan 1992 A
5080674 Jacobs et al. Jan 1992 A
5080685 Bolesky et al. Jan 1992 A
5092897 Forte Mar 1992 A
5096518 Fujikawa et al. Mar 1992 A
5098435 Stednitz et al. Mar 1992 A
5104410 Chowdhary Apr 1992 A
5108432 Gustavson Apr 1992 A
5133764 Pappas et al. Jul 1992 A
5152796 Slamin Oct 1992 A
5152797 Luckman et al. Oct 1992 A
5156626 Broderick et al. Oct 1992 A
5163961 Harwin Nov 1992 A
5167502 Kawahara et al. Dec 1992 A
5176711 Grimes Jan 1993 A
5181928 Bolesky et al. Jan 1993 A
5192329 Christie et al. Mar 1993 A
5198308 Shetty et al. Mar 1993 A
5201766 Georgette Apr 1993 A
5203787 Noblitt et al. Apr 1993 A
5211665 Ku May 1993 A
5226915 Bertin Jul 1993 A
5236457 Devanathan Aug 1993 A
5236462 Mikhail Aug 1993 A
5246530 Bugle et al. Sep 1993 A
5282861 Kaplan Feb 1994 A
5286260 Bolesky et al. Feb 1994 A
5290315 DeCarlo, Jr. Mar 1994 A
5310408 Schryver et al. May 1994 A
5314490 Wagner et al. May 1994 A
5323954 Shetty et al. Jun 1994 A
5326367 Robioneck et al. Jul 1994 A
5326368 Collazo Jul 1994 A
5343877 Park Sep 1994 A
5348788 White Sep 1994 A
5358532 Evans et al. Oct 1994 A
5360448 Thramann Nov 1994 A
5360452 Engelhardt et al. Nov 1994 A
5370692 Fink et al. Dec 1994 A
5370698 Heimke et al. Dec 1994 A
5370702 Jones Dec 1994 A
5370704 DeCarlo, Jr. Dec 1994 A
5370706 Bolesky et al. Dec 1994 A
5376122 Pappas et al. Dec 1994 A
5380325 Lahille et al. Jan 1995 A
5397359 Mittelmeier et al. Mar 1995 A
5405389 Conta et al. Apr 1995 A
5415704 Davidson May 1995 A
5443510 Shetty et al. Aug 1995 A
5443512 Parr et al. Aug 1995 A
5443519 Averill et al. Aug 1995 A
5484539 Tersi et al. Jan 1996 A
5486181 Cohen et al. Jan 1996 A
5496372 Hamamoto et al. Mar 1996 A
5504300 Devanathan et al. Apr 1996 A
5505984 England et al. Apr 1996 A
5509933 Davidson et al. Apr 1996 A
5534027 Hodorek Jul 1996 A
5535810 Compton et al. Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5545227 Davidson et al. Aug 1996 A
5549685 Hayes Aug 1996 A
5549691 Harwin Aug 1996 A
5549698 Averill et al. Aug 1996 A
5549701 Mikhail Aug 1996 A
5571187 Devanathan Nov 1996 A
5571194 Gabriel Nov 1996 A
5571198 Drucker et al. Nov 1996 A
5571200 Cohen et al. Nov 1996 A
5571201 Averill et al. Nov 1996 A
5573401 Davidson et al. Nov 1996 A
5593451 Averill et al. Jan 1997 A
5609641 Johnson et al. Mar 1997 A
5609645 Vinciguerra Mar 1997 A
5609646 Field et al. Mar 1997 A
5639280 Warner et al. Jun 1997 A
5658338 Tullos et al. Aug 1997 A
5658347 Sarkisian et al. Aug 1997 A
5658348 Rohr, Jr. Aug 1997 A
5665119 Koller Sep 1997 A
5676700 Black et al. Oct 1997 A
5676704 Ries et al. Oct 1997 A
5688453 England et al. Nov 1997 A
5702473 Albrektsson et al. Dec 1997 A
5702477 Capello et al. Dec 1997 A
5702483 Kwong Dec 1997 A
5702487 Averill et al. Dec 1997 A
5723011 Devanathan et al. Mar 1998 A
5723014 Laurent et al. Mar 1998 A
5725587 Garber Mar 1998 A
5728510 White Mar 1998 A
5734959 Krebs et al. Mar 1998 A
5755743 Volz et al. May 1998 A
5755806 Stalcup et al. May 1998 A
5782928 Ries et al. Jul 1998 A
5782929 Sederholm Jul 1998 A
5798308 Chatterjee et al. Aug 1998 A
5824107 Tschirren Oct 1998 A
5824108 Huebner Oct 1998 A
5863295 Averill et al. Jan 1999 A
5871548 Sanders et al. Feb 1999 A
5879398 Swarts et al. Mar 1999 A
5879399 Church Mar 1999 A
5879401 Besemer et al. Mar 1999 A
5879404 Bateman et al. Mar 1999 A
5879405 Ries et al. Mar 1999 A
5888205 Pratt et al. Mar 1999 A
5904720 Farrar et al. May 1999 A
5916268 Schollner et al. Jun 1999 A
5925077 Williamson et al. Jul 1999 A
5926685 Krebs et al. Jul 1999 A
5931870 Cuckler et al. Aug 1999 A
5938702 Lopez et al. Aug 1999 A
5972032 Lopez et al. Oct 1999 A
5976148 Charpenet et al. Nov 1999 A
5981828 Nelson et al. Nov 1999 A
5989293 Cook et al. Nov 1999 A
6008432 Taylor Dec 1999 A
6013104 Kampner Jan 2000 A
6022509 Matthews et al. Feb 2000 A
6042611 Noiles Mar 2000 A
6042612 Voydeville Mar 2000 A
6049054 Panchison et al. Apr 2000 A
6063442 Cohen et al. May 2000 A
6066176 Oshida May 2000 A
6087553 Cohen et al. Jul 2000 A
6099529 Gertzman et al. Aug 2000 A
6129765 Lopez et al. Oct 2000 A
6132469 Schroeder Oct 2000 A
6132674 Compton et al. Oct 2000 A
6136029 Johnson et al. Oct 2000 A
6139574 Vacanti et al. Oct 2000 A
6143036 Comfort Nov 2000 A
6143293 Weiss et al. Nov 2000 A
6149689 Grundei Nov 2000 A
6152962 DeCarlo, Jr. Nov 2000 A
6162257 Gustilo et al. Dec 2000 A
6165222 Hoeppner et al. Dec 2000 A
6176879 Reischl et al. Jan 2001 B1
6187050 Khalili et al. Feb 2001 B1
6192272 Fiedler Feb 2001 B1
6193761 Treacy Feb 2001 B1
6197065 Martin et al. Mar 2001 B1
6203844 Park Mar 2001 B1
6206924 Timm Mar 2001 B1
6217620 Park Apr 2001 B1
6228121 Khalili May 2001 B1
6231612 Balay et al. May 2001 B1
6240616 Yan Jun 2001 B1
6253443 Johnson Jul 2001 B1
6273891 Masini Aug 2001 B1
6290726 Pope et al. Sep 2001 B1
6293971 Nelson et al. Sep 2001 B1
6296667 Johnson et al. Oct 2001 B1
6302913 Ripamonti et al. Oct 2001 B1
6306173 Masini Oct 2001 B1
6309546 Herrmann et al. Oct 2001 B1
6322728 Brodkin et al. Nov 2001 B1
6340370 Willert et al. Jan 2002 B1
6352559 Church Mar 2002 B1
6365092 Backa et al. Apr 2002 B1
6376573 White et al. Apr 2002 B1
6391251 Keicher et al. May 2002 B1
6416553 White et al. Jul 2002 B1
6432142 Kamiya et al. Aug 2002 B1
6443991 Running Sep 2002 B1
6447543 Studer et al. Sep 2002 B1
6447550 Hunter et al. Sep 2002 B1
6454811 Sherwood et al. Sep 2002 B1
6458161 Gibbs et al. Oct 2002 B1
6461385 Gayer et al. Oct 2002 B1
6475243 Sheldon et al. Nov 2002 B1
6497727 Pope et al. Dec 2002 B1
6506192 Gertzman et al. Jan 2003 B1
6508841 Martin et al. Jan 2003 B2
6520995 Church Feb 2003 B2
6527774 Lieberman Mar 2003 B2
6527807 O'Neil et al. Mar 2003 B1
6530958 Cima et al. Mar 2003 B1
6537321 Horber Mar 2003 B1
6558428 Park May 2003 B2
6572655 Johnson Jun 2003 B1
6585772 Hunter et al. Jul 2003 B2
6592622 Ferguson Jul 2003 B1
6605293 Giordano et al. Aug 2003 B1
6605648 Johnson et al. Aug 2003 B1
6610097 Serbousek et al. Aug 2003 B2
6613093 DeCarlo, Jr. et al. Sep 2003 B2
6620200 Descamps et al. Sep 2003 B1
6621039 Wang et al. Sep 2003 B2
6626947 Lester et al. Sep 2003 B2
6641616 Grundei Nov 2003 B1
6645206 Zdeblick et al. Nov 2003 B1
6652586 Hunter et al. Nov 2003 B2
6660040 Chan et al. Dec 2003 B2
6660224 Lefebvre et al. Dec 2003 B2
RE38409 Noiles Jan 2004 E
6676704 Pope et al. Jan 2004 B1
6676892 Das et al. Jan 2004 B2
6682566 Draenert et al. Jan 2004 B2
6682567 Schroeder Jan 2004 B1
6686437 Buchman et al. Feb 2004 B2
6695884 Townley Feb 2004 B1
6696073 Boyce et al. Feb 2004 B2
6709462 Hanssen Mar 2004 B2
6725901 Kramer et al. Apr 2004 B1
6726723 Running Apr 2004 B2
6726725 Hunter et al. Apr 2004 B2
6758864 Storer et al. Jul 2004 B2
6770099 Andriacchi et al. Aug 2004 B2
6783551 Metzger et al. Aug 2004 B1
6800094 Burkinshaw Oct 2004 B2
6811569 Afriat et al. Nov 2004 B1
6827742 Hayes, Jr. et al. Dec 2004 B2
6840960 Bubb Jan 2005 B2
6866685 Chan et al. Mar 2005 B2
6869447 Lee et al. Mar 2005 B2
6896703 Barbieri et al. May 2005 B2
6908486 Lewallen Jun 2005 B2
6916342 Frederick et al. Jul 2005 B2
6923833 Wasielewski Aug 2005 B2
6926740 Lewis et al. Aug 2005 B2
6945448 Medlin et al. Sep 2005 B2
7141073 May et al. Nov 2006 B2
20010011190 Park Aug 2001 A1
20010013166 Yan Aug 2001 A1
20010030035 Oda Oct 2001 A1
20020016635 Despres, III et al. Feb 2002 A1
20020040245 Lester et al. Apr 2002 A1
20020062154 Ayers May 2002 A1
20020068980 Serbousek et al. Jun 2002 A1
20020123750 Eisermann et al. Sep 2002 A1
20020139504 Klein Oct 2002 A1
20020151983 Shetty Oct 2002 A1
20020197178 Yan Dec 2002 A1
20030001282 Meynen et al. Jan 2003 A1
20030013989 Obermiller et al. Jan 2003 A1
20030033020 Hunter et al. Feb 2003 A1
20030049299 Malaviya et al. Mar 2003 A1
20030050703 Harris et al. Mar 2003 A1
20030050705 Cueille et al. Mar 2003 A1
20030069639 Sander et al. Apr 2003 A1
20030083741 Woo et al. May 2003 A1
20030105529 Synder et al. Jun 2003 A1
20030111752 Wood et al. Jun 2003 A1
20030114936 Sherwood et al. Jun 2003 A1
20030135281 Hanssen Jul 2003 A1
20030144741 King et al. Jul 2003 A1
20030144742 King et al. Jul 2003 A1
20030153981 Wang et al. Aug 2003 A1
20030153982 Pria Aug 2003 A1
20030155686 Hawkins et al. Aug 2003 A1
20030163203 Nycz et al. Aug 2003 A1
20030171818 Lewallen Sep 2003 A1
20030200837 Matsuura et al. Oct 2003 A1
20030220696 Levine et al. Nov 2003 A1
20030232124 Medlin et al. Dec 2003 A1
20030236573 Evans et al. Dec 2003 A1
20040054418 McLean et al. Mar 2004 A1
20040054421 McLean Mar 2004 A1
20040064192 Bubb Apr 2004 A1
20040072010 Date et al. Apr 2004 A1
20040083004 Wasielewski Apr 2004 A1
20040088038 Dehnad et al. May 2004 A1
20040098127 Charlebois et al. May 2004 A1
20040102854 Zhu May 2004 A1
20040109853 McDaniel Jun 2004 A1
20040122521 Lee et al. Jun 2004 A1
20040126265 Takiguchi Jul 2004 A1
20040126583 Nakamura et al. Jul 2004 A1
20040137218 Liu et al. Jul 2004 A1
20040166340 Cairns et al. Aug 2004 A1
20040172137 Blaylock et al. Sep 2004 A1
20040186553 Yan Sep 2004 A1
20040199258 Macara Oct 2004 A1
20040199260 Pope et al. Oct 2004 A1
20040210316 King et al. Oct 2004 A1
20040225369 Lakin et al. Nov 2004 A1
20040225371 Roger Nov 2004 A1
20040229029 Bowles et al. Nov 2004 A1
20040238410 Inoue et al. Dec 2004 A1
20040243133 Materna Dec 2004 A1
20050004677 Johnson Jan 2005 A1
20050004678 Richards Jan 2005 A1
20050004680 Saladino et al. Jan 2005 A1
20050010303 Nogier Jan 2005 A1
20050025656 Bhaduri et al. Feb 2005 A1
20050031704 Ahn Feb 2005 A1
20050032025 Bhaduri et al. Feb 2005 A1
20050035052 Kelly et al. Feb 2005 A1
20050048193 Li et al. Mar 2005 A1
20050049713 Garber et al. Mar 2005 A1
20050060040 Auxepaules et al. Mar 2005 A1
20050065307 King et al. Mar 2005 A1
20050065604 Stoll Mar 2005 A1
20050071015 Sekel Mar 2005 A1
20050085820 Collins et al. Apr 2005 A1
20050085915 Steinberg Apr 2005 A1
20050087915 Pope et al. Apr 2005 A1
20050090905 Hawkins et al. Apr 2005 A1
20050100470 Lefebvre et al. May 2005 A1
20050107883 Goodfried et al. May 2005 A1
20050145364 Nakajima Jul 2005 A1
20050171614 Bacon Aug 2005 A1
20050184134 Charlebois et al. Aug 2005 A1
20050234559 Fernandez et al. Oct 2005 A1
20050246032 Bokros et al. Nov 2005 A1
20060002810 Grohowski Jan 2006 A1
20060003179 Wang et al. Jan 2006 A1
20060018942 Rowe et al. Jan 2006 A1
20060241776 Brown et al. Oct 2006 A1
20060241781 Brown et al. Oct 2006 A1
20070129809 Meridew et al. Jun 2007 A1
20070173948 Meridew et al. Jul 2007 A1
20070250175 Meridew et al. Oct 2007 A1
20070264152 Zhao Nov 2007 A1
20080147187 Bollinger et al. Jun 2008 A1
Foreign Referenced Citations (32)
Number Date Country
24 04 214 Jan 1974 DE
3130732 May 1983 DE
3205526 Sep 1983 DE
41 33 433 May 1993 DE
0612509 Aug 1994 DE
19726961 Nov 1998 DE
0 214 885 Jul 1986 EP
0214885 Mar 1987 EP
0 378 928 Jul 1990 EP
0 538 987 Apr 1993 EP
0551794 Jul 1993 EP
0648478 Apr 1995 EP
0 807 426 Nov 1997 EP
0 985 386 Mar 2000 EP
1082949 Mar 2001 EP
1 236 450 Sep 2002 EP
0 806 921 Jan 2003 EP
1 384 456 Jan 2004 EP
1421918 May 2004 EP
1 430 856 Jun 2004 EP
2 148 322 Mar 1973 FR
2775586 Sep 1999 FR
2001247 Jan 1979 GB
WO 9218069 Apr 1992 WO
WO 9623459 Jan 1996 WO
WO 9613233 May 1996 WO
WO 0038598 Jul 2000 WO
WO 0207652 Jul 2001 WO
WO-0170141 Sep 2001 WO
WO-2004069107 Aug 2004 WO
WO 2004080340 Sep 2004 WO
WO-2006007861 Jan 2006 WO
Related Publications (1)
Number Date Country
20070196230 A1 Aug 2007 US